ncRNA basic information ncRNA ID: ENSG00000224057 ncRNA Database: Ensembl ncRNA Name: EGFR-AS1 ncRNA Type: lncRNA ncRNA Expression: up-regulated ncRNA Method: RT-qPCR ncRNA Target Gene: IGF1R ncRNA Pathway: IGF1R/AKT/PI3K signaling pathway Evidence (ncRNA-drug): validated

drug basic information Drug ID: DB00515 (APRD00359) Drug Name: Cisplatin Drug Method: The present study aimed to investigate the effect of lncRNAs on NSCLC resistance to chemotherapy. The relative expression level of epidermal growth factor receptor antisense RNA 1 (EGFR-AS1) was quantified by reverse transcription-quantitative polymerase chain reaction analysis in NSCLC tissues, paired adjacent normal tissues, patient plasma and NSCLC cell lines, and its association with prognosis was assessed by multivariate analysis. The biological functions of EGFR-AS1 in NSCLC cells were determined in vitro. It was found that EGFR-AS1 was abnormally upregulated in NSCLC tissues compared with adjacent normal lung tissues. Furthermore, patients with NSCLC with increased expression of EGFR-AS1 had a poor prognosis. EGFR-AS1 knockdown significantly inhibited NSCLC malignancy in vitro, including cell proliferation and chemoresistance. Furthermore, the expression levels of EGFR-AS1 were increased in plasma samples from patients with cisplatin-based chemotherapy resistance. Bioinformatics analysis and a luciferase reporter assay confirmed that EGFR-AS1 mediated cell proliferation and chemoresistance through directly binding to microRNA-223. Therefore, EGFR-AS1 overexpression-induced chemoresistance can contribute to poor prognosis in NSCLC. Drug Response: resistant

Cancer basic information Cancer: lung non-small cell carcinoma Tissue/Cell: cell line ( A549, NCI-H460,NCI-H1299, NCI-H358, HCC827, NCI-H292, NCI-H838)

Other information Title: Overexpression of lncRNA EGFR-AS1 is associated with a poor prognosis and promotes chemotherapy resistance in non-small cell lung cancer. Journal: Int J Oncol Published: 2019 PubMed ID: 30431074